OSUR enters the week before its June 3 earnings with a split insider register — one director buying steadily into weakness while others quietly reduce their exposure.
Director Steven Kyle Boyd has purchased 75,000 shares across three consecutive trading days this week, paying between $2.98 and $2.99 per share for a total outlay of roughly $224,750. On the same two days Boyd was buying, three fellow board members — Gagliano, McMahon, and Marmora — were selling combined stakes worth nearly $220,000. The two-way traffic is unusual in both its symmetry and its timing, five days before the next results. Boyd's purchases carry a trade significance score of 3, above the 1 assigned to the director sells, suggesting the buying is being flagged as more deliberate. The net picture over 90 days is firmly positive: insiders have bought roughly 480,000 more shares than they've sold, worth approximately $1.45 million. CEO Carrie Eglinton Manner and CFO Kenneth McGrath both added shares in March at prices around $2.93, adding to the signal that company leadership sees value near current levels.
Short positioning is a secondary story here, not the headline. Short interest is 4.3% of the free float — meaningful but not extreme — and has been drifting lower for a month, down roughly 12.5% over that stretch. The borrow market reinforces the cautious-rather-than-aggressive read: cost to borrow has collapsed to just 0.34%, down more than 42% on the week and nearly 40% over the past month, having briefly touched 1.42% in late April. Availability is ample. The ORTEX short score is 46.8, broadly mid-range, and has barely moved this week. There is no squeeze dynamic building here.
Options positioning has picked up relative to its recent norm, though the starting point is very low. The put/call ratio has risen to 0.044 from a 20-day average of 0.024 — technically 1.4 standard deviations above that average — but both figures reflect a market where call activity heavily dominates. The PCR 52-week range runs from 0.006 to 0.21, so the current reading remains near the bottom of the historical range. Options traders are not pricing in material downside ahead of the June print.
The Street is uninspiring for bulls. The mean analyst price target is $4.75 against a current price of $3.00 — implying about 58% upside on paper — but the two most recent analyst actions on record, both from Stephens and Evercore ISI in late 2025, maintained neutral/in-line ratings. Evercore cut its target from $4.00 to $3.00 in May 2025 and held it there. Stephens lowered its target from $3.50 to $3.00 in November. Neither firm has moved since, which suggests the Street is watching rather than acting. Older JPMorgan and Citigroup targets from 2024 (ranging from $6 to $9) are too stale to be meaningful at current price levels. The stock trades at just 0.66x book value, and EV/EBITDA is barely above 1x — multiples consistent with a company that has disappointed repeatedly but where valuation has compressed to the point of reflecting most of the bad news. EPS surprise ranks in the 90th percentile of the universe, an unusually high bar for a stock this cheap. Earnings history backs that up: the most recent print in early May produced a 4.3% next-day gain, and the February event moved the stock +12.5% in a single session.
Peers had a rough week. ENOV fell 8.4% and INGN lost 9.1% over the same period. OSUR closed down just under 2% on the week, faring better on a relative basis. BlackRock holds 9.4% of shares and added modestly in April, while Altai Capital trimmed 127,000 shares — the only notable institutional reduction in the top 15.
The next focal point is the June 3 earnings call, where the tension between a high EPS surprise track record, a deeply discounted valuation, and a flat analyst consensus will meet a fresh set of numbers.
See the live data behind this article on ORTEX.
Open OSUR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
